Dr. David Miller
David completed his PhD in heterocyclic chemistry at Hull University before going on to post-doc with Professor Chris Moody (Loughborough University) and then Professor Andreas Pfaltz (Max Planck Institute). His first industrial position was at Organon Laboratories in Newhouse, Scotland where he spent over 5 years as a chemistry and project team leader, working on schizophrenia, pain and depression programs. In 2002 David moved to Cambridge to take up a senior role at Amedis Pharmaceuticals, which subsequently merged with Paradigm Therapeutics and the combined company was later acquired by the Takeda Pharmaceutical Company. At Takeda, David was a parallel project leader, leading the team that delivered a compound into the clinic for a challenging CNS target. Upon leaving Takeda he was Associate Director within the Medicinal Chemistry department having with responsibility for analytical chemistry and DMPK. David currently has 16 scientific publications and is a named inventor on 9 patents.
Pharmaceutical Medicinal Chemistry